TAI'AN, China, Jan. 4, 2011 /PRNewswire-Asia-FirstCall/ -- China
Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic or the
"Company"), one of the leading plasma-based biopharmaceutical
companies in the People's Republic of
China, today announced that NASDAQ has notified it that the
Company has met the initial listing requirements for the NASDAQ
Global Select Market. Therefore, beginning January 3, 2011, China Biologic is now included
in the NASDAQ Global Select Market.
Mr. Chao Ming Zhao, Chief
Executive Officer of China Biologic, said, "I believe that being
included in the NASDAQ Global Select Market is a good indicator
that we are on the right road to achieving our long-term operating
and financial goals for the Company, which include creating value
for shareholders. We are both very pleased and honored to be
included in NASDAQ's highest market tier."
NASDAQ Global Select Market: The world's
highest standards
According to NASDAQ, the NASDAQ Global Select Market(SM) is for
public companies that meet the highest listing standards in the
world, with measures including market value, liquidity, and
earnings. Inclusion in the NASDAQ Global Select Market is a mark of
achievement and stature for qualified companies. Listing on NASDAQ
represents companies' commitment to provide investors with superior
market quality. Investors benefit not only from lower trading costs
on NASDAQ but also by knowing that NASDAQ Global Select Market
companies are models of leadership and have met the highest
standards of any market in the world. Companies qualifying for the
NASDAQ Global Select Market make up approximately one-third of
NASDAQ listings and reflect the diversity of NASDAQ as a whole, in
terms of market cap and across industry sectors, according to
NASDAQ.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products
Co., Ltd., and Guiyang Dalin Biologic Technologies Co., Ltd., and
its equity investment in Xi'an Huitian Blood Products Co., Ltd., is
currently one of the leading plasma-based biopharmaceutical
companies in China. The Company is
a fully integrated biologic products company with plasma
collection, production and manufacturing, research and development,
and commercial operations. The Company's plasma-based
biopharmaceutical products are irreplaceable during medical
emergencies and are used for the prevention and treatment of
various diseases. The Company sells its products to hospitals and
other healthcare facilities in China. For additional information, please see
the Company's website at http://www.chinabiologic.com.
Company
Contact:
|
|
Mr. Y. Tristan
Kuo
|
|
Chief Financial
Officer
|
|
China Biologic Products,
Inc.
|
|
Telephone: +86-538-6202206
in China
|
|
Email: IR@chinabiologic.com
|
|
www.chinabiologic.com
|
|
|
SOURCE China Biologic Products, Inc.